Zimmer Biomet (ZBH) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Zimmer Biomet (ZBH) do?
Zimmer Biomet Holdings Inc (ZBH) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures orthopedic implants, surgical tools, and robotic guidance systems for hospitals. It designs and manufactures artificial knees, hips, and surgical robotics used in joint reconstruction procedures. It is worth $19.20B on the market and sold $8.57B over the last year.
- Market cap
- $19.20B
- P/E ratio
- 25.7×
- Annual sales
- $8.57B
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 13, 2026
Brands and businesses behind ZBH
- ROSA: Sells robotic surgical assistants and compatible procedural instruments to hospital operating rooms.
- Persona: Produces personalized artificial knee implants and surgical instruments sold to orthopedic centers.
- Oxford: Manufactures partial knee replacement implants designed to repair single compartments of damaged joints.
- G7 Acetabular System: Supplies modular hip socket replacement implants and fixation instruments to surgeons.
- Avenir Complete: Sells femoral stems and instrumentation kits used in primary hip replacement surgeries.
- Signature ONE: Provides patient-specific surgical guides and preoperative planning software for joint procedures.
ZBH’s flags, in plain English
Each flag is a number from Zimmer Biomet’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.
Wide Gross Margin
Gross margin of 61.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Low debt
Low debt, only 59% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Cheap on Cash Flow
Priced at 14.8 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Growth Cooling
Sales growth slowed to 3.2% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.
Questions about ZBH
How big is Zimmer Biomet?
Zimmer Biomet’s market cap is $19.20B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $8.57B: what customers paid the company over the last year, before any costs.
What is ZBH’s P/E ratio?
ZBH’s P/E ratio is 25.7×. Investors pay about 25.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ZBH?
Revenues depend heavily on elective reconstructive surgeries that hospitals can defer during staffing shortages or budget constraints. That is one risk on Zimmer Biomet’s card. Its first risk flag is Growth Cooling, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Zimmer Biomet’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ZBH’s filings on SEC.gov. The Margin Monkey is research, not advice.
